bpc 157 for acl recovery BPC-157 Injectable Peptide Healing & Orthopedic Use of BPC-157 -

(Academic, 2023)

For example, Galea et al

Conflict of interest EB and GT were employed by PharmaNutra S.p.A, Pisa, Italy

A dose increase may not be needed when the current dose is already effective

According to the exploration results of the T1D patients or models, the following bacteria were mainly increased in abundance: Bifidobacterium longum (166, 167), Eubacterium rectale (168), Bacteroides uniformis (169), Lachnospira spp., Intestinimonas spp., Micrococcales spp (170)., Actinomyces spp (171)., Bacteroides spp (172)., Prevotella spp (168)., Ruminococcus spp (173)., and Veillonella spp (174)., whereas the bacterium with decreased abundance mainly includes butyrate-producing bacterium, lactic acid-producing bacterium, and mucin-degrading bacterium, such as Lactococcus , Lactobacillus ( 173), Streptococcus (174), Bifidobacterium , Proteobacteria (172), Subdoligranulum , Roseburia , Eubacterium , Anaerostipes (175), FP (176, 177), Clostridium clusters IV (178, 179), and XIVa (180, 181)

In such cases, the focus should shift to investigating potential underlying causessuch as myeloproliferative disorders, liver disease, or renal dysfunctionrather than attributing symptoms to the elevated B12 itself